Celea Therapeutics is a PureTech-founded respiratory biotherapeutics company focused on deupirfenidone (LYT-100) for idiopathic pulmonary fibrosis and related fibrotic lung diseases. It launched in 2025 as a wholly owned subsidiary of PureTech.
PureTech Health announced that deupirfenidone has received Orphan Drug Designation from both the U.S. FDA and European Commission for idiopathic pulmonary fibrosis, with a Phase 3 trial planned for the first half of 2026.
PureTech Health's deupirfenidone has received Orphan Drug Designation from both the U.S. FDA and European Commission for treating idiopathic pulmonary fibrosis, a rare and fatal lung disease. Phase 2b trial results showed superior efficacy compared to existing therapies.
